2015 ACR/ARHP Annual Meeting Abstract Supplement

4053 Pages·2015·60.73 MB·English

Volume 67 • Number S10 • October 2015
ABSTRACT SUPPLEMENT
2015 ACR/ARHP ANNUAL MEETING
November 6–11, 2015
San Francisco, CA
WWiilleeyy__AARRTT__CCoovveerr__ss1100..iinndddd 11 2266//0099//1155 22::1177 PPMM
Accreditation Statement: The American College of 7. Receipt of royalties
Rheumatology is accredited by the Accreditation Council for 8. Speakers’ bureau
Continuing Medical Education (ACCME) to provide 9. Other
continuing medical education for physicians. None: Nothing to disclose
Abstract author disclosures are published online. Any
Designation Statement: The ACR designates this live individual who refuses to disclose relevant financial
educational activity for a maximum of 54.50 AMA PRA relationships is ineligible to serve as a planning committee
Category 1 Credits™. Physicians should claim only the credit member, presenter or author of an ACR CME activity, and
commensurate with the extent of their participation in the cannot have control of, or responsibility for, the development,
activity. management, presentation or evaluation of the CME activity.

International Physicians: International physicians who Abstract Embargo Policy
register as part of a group and require AMA PRA Category 1 Accepted abstracts are made available to the public online in
Credit(s)™ must provide the following information to your advance of the meeting and are published in a special online
tour leader: full name, mailing address, telephone and fax abstract supplement of the Arthritis & Rheumatology
numbers and e-mail address. The information will be used to journal. Information contained in those abstracts may not be
verify your meeting attendance. released until the abstracts appear online. Academic
institutions, private organizations and companies with
The American Medical Association has an agreement of products whose value may be influenced by information
mutual recognition of continuing medical education credit contained in an abstract may issue a press release to coincide
with the European Union of Medical Specialties. International with the availability of an ACR abstract on the ACR
physicians interested in converting AMA PRA Category 1 website. However, the ACR continues to require that
Credit™ to EACCME credit should contact the UEMS. information that goes beyond that contained in the abstract
(e.g., discussion of the abstract done as part a scientific
Health Professionals: Participants may claim hours to receive presentation or presentation of additional new information that
a Certificate of Participation for an activity designated for will be available at the time of the meeting) is under embargo
AMA PRA Category 1 Credit(s)™. For non-CME sessions, until 4:30 PM Pacific Time on Saturday, November 7,
attendees may also request a certificate of participation. 2015.

Disclosure Policy Violation of this policy may result in the abstract being
It is the policy of the American College of Rheumatology to withdrawn from the meeting and other measures deemed
ensure that its CME activities are independent and free of appropriate. Authors are responsible for notifying financial
commercial bias. To ensure content objectivity and balance, and other sponsors about this policy. If you have questions
and guarantee that the content presented is in the best interest about the abstract embargo policy, please contact the public
of its learners and the public, the ACR requires that all relations department at [email protected].
individuals in a position to control content disclose all relevant
financial relationships with any commercial interest if the Copyright Policy
relationship is financial and occurred within the past 12 The annual meeting is a private event. Programs presented at
months. This includes the relationships of spouse/partners. If the meeting are for the education of attendees and purchasers
there are relationships that create a conflict of interest, these of recorded presentations as authorized by the American
must be resolved in accordance with the ACR’s CME College of Rheumatology. The information and materials
Resolution of Conflict policy prior to the participation of the displayed and presented during this meeting are the property
individual in the development or presentation of CME content. of the ACR and the presenter and cannot be photographed,
copied, photocopied, transformed to electronic format,
As an educational provider accredited by the Accreditation reproduced, or distributed without written permission of the
Council for Continuing Medical Education, the American American College of Rheumatology and the presenter. Any
College of Rheumatology must ensure balance, independence, use of the program content for commercial purposes, which
objectivity and scientific rigor in all its educational activities. includes, but is not limited to oral presentations, audiovisual
Therefore, all those in a position to control content (e.g., materials used by speakers, and program handouts without the
speakers and moderators) participating in an ACR-sponsored written consent of the ACR is prohibited. This policy applies
activity are required to disclose to the planning committee and before, during and after the meeting. The ACR will enforce its
audience any financial or other relationships including, but not intellectual property rights and penalize those who infringe
limited to: upon it.

1. Stock, stock options or bond holdings in a for-
profit corporation or self-directed pension plan The names, insignias, logos and acronyms of the ACR, the
2. Research grants ARHP and the Rheumatology Research Foundation are
3. Employment (full or part time) proprietary marks. Use of the names in any fashion, by any
4. Ownership or partnership entity, for any purpose, is prohibited without the express
5. Consulting fees or other remuneration (payment) written permission of the American College of Rheumatology.
6. Non-remunerative positions of influence such as Attendees who have questions about the ACR’s copyright
officer, board member, trustee or public policy should contact the public relations department
spokesperson at [email protected].
• Permission requests for abstract content and other
Media permission inquiries should be addressed to:
Credentialed media attend the annual meeting to cover stories Permissions Department
for consumer, trade and other media outlets, and are easily c/o John Wiley & Sons, Inc.
identified by their black press ribbons. Media has access to all 111 River Street
general sessions and limited access (at the discretion of Hoboken, NJ 07030
speakers) to Meet the Professor and Workshop sessions. Fax: [phone]
Media may use hand-held audio recorders and still cameras; wiley.com/go/permissions
moving video recording is also permitted with the permission • Commercial entities seeking permission to reprint
of the presenter(s). The exception to this policy is that no must obtain all materials from the author and/or
photos or video are allowed in the Exhibit Hall and no publisher John Wiley & Sons, Inc.
photos or video are allowed in the Poster Hall without • ACR cannot provide any materials.
permission from the poster presenter. Press who would like
general photos of the Exhibit Hall can obtain these after the Reproducing ACR Abstracts and ACR Posters for
meeting from the ACR. Attendees who have questions about Dissemination Prior to the Annual Meeting
the ACR’s media policies should contact the public relations • Requests to reproduce abstracts for dissemination
department at [email protected]. prior to the annual meeting will not be approved.
• Per the ACR Embargo Policy, academic institutions,
Photographs and Video Recording Policy
private organizations and companies with products
As a courtesy to our presenters, ACR policy does not permit
whose value may be influenced by information
photographs or recordings during educational sessions,
contained in an abstract may issue a press release to
including poster sessions. The only exception to this is for
coincide with the availability of an abstract online.
registered media, who should review their registration
• Permission to issue a press release does not require
materials for more information.
ACR approval. However, it must comply with

the ACR Embargo Policy; violation of this policy
Abstract Reprint (Reproduction) Policy
may result in the abstract being withdrawn from the
Copyright law covers all annual meeting abstracts published
meeting or other measures deemed appropriate.
by the American College of Rheumatology. All rights
• For more information regarding press releases, please
reserved. No abstracts may be reproduced in any form or by
contact the ACR Public Relations Department
any means, except as permitted under section 107 and 108 of
at [email protected].
the 1976 United States Copyright Act, without the prior

permission of the publisher.
Reproducing ACR Abstracts and ACR Posters for

Dissemination During the Annual Meeting
For the purposes of this statement, the term “ACR
Following approval (see approval process above), an
Abstracts” refers to all annual meeting abstracts as published
exhibiting organization may:
in Arthritis & Rheumatology and posted online, including the
• Disseminate copies of individual ACR Abstracts
abstracts accepted for presentation during ARHP sessions and
from its exhibit space. Booklets of abstracts (e.g., two
the late-breaking category.
or more) may not be produced.

• Disseminate information summaries
For the purposes of this statement, the term “ACR
(title/date/time/poster number) of ACR Abstracts
Posters” refers to the accepted abstract POSTER
from its exhibit space.
PRESENTATIONS as presented in the poster hall during the
• Summaries may not reference company or product
annual meeting. This does not include abstract text
names. Requests for approval must be submitted in
published in the online supplement of Arthritis &
writing to [email protected].
Rheumatology. All ACR Posters are the property of the ACR
• Presenting authors may disseminate individual copies
or the presenting author and cannot be reproduced or
of their ACR Poster during their assigned poster
distributed without written permission from the ACR and the
presentation time.
presenting author.
For the purposes of this statement, the term “reproduce” • Dissemination must be limited to the area directly in
includes all forms of reproduction including, but not limited front of their assigned poster space and may not
to, print, electronic and photographed formats. interfere with other poster presentations.
• An electronic copy of the poster may be provided via
For the purposes of this statement, the term “presenting a QR code generated by the presenter and included
author” refers to the author who is designated as the individual on the poster
who will present the work during the ACR annual meeting, as
identified through the abstract submission process. Reproducing ACR Abstracts and ACR Posters for
Dissemination After the Annual Meeting
Abstract Reprint Approval Process ACR Abstracts
• Excerpts of ACR Abstracts or ACR Poster Following approval (see approval process above), the ACR
Presentations in their entirety may not be permits ACR Abstracts (i.e., all abstract content published in
reproduced without the prior written permission of the online supplement) to be reprinted and disseminated
the publisher. following the annual meeting.
• Booklets of abstracts (e.g., two or more) must include Use of the ACR Name
the following statement on the front of the booklet: • The names, insignias, logos and acronyms of the
Abstract(s) reprinted from the ACR/ARHP Annual ACR, the ARHP and the Rheumatology Research
Meeting held November 6-11, 2015. The American Foundation are proprietary marks.
College of Rheumatology does not guarantee, warrant, or • Use of the names in any fashion, by any entity, for
endorse any commercial products or services. Reprinted
any purpose, is prohibited without the written
by (insert name of supporting company).
permission of the ACR.
• Booklets cannot contain corporate or product logos or

any advertisements. No exceptions.
Use of the ACR Scientific Program Content

• Information displayed or presented at all sessions
ACR Poster Presentations
during the annual meeting is the property of the ACR
Following approval from the presenting author and ACR,
or the presenter. Information may not be recorded,
copies of actual ACR poster presentations (i.e. images of the
photographed, copied, photocopied, transferred to
poster presentation hung in the poster hall) may be
electronic format, reproduced or distributed without
reproduced.
the written permission of the ACR and the presenter.
• Reprint requests for the actual poster abstract
• Any use of the program content, which includes but
text published in the Arthritis &
is not limited to oral presentations, audiovisual
Rheumatology supplement are considered ACR
materials used by speakers and program handouts,
Abstracts and must submitted to Wiley (see approval
without the written consent of the ACR is prohibited.
process above).
• This policy applies before, during and after the
• Requests to reproduce individual ACR poster or
meeting.
booklets of poster presentations (e.g., two or more)
• The ACR will enforce its intellectual property rights
must be submitted via e-mail to
and penalize those who infringe upon it.
[email protected].
• Poster reproduction requests must include the
following:
Abstract ID Number
o
Abstract Title
o
o Presenting Author’s Name
o A copy of Presenting Author’s written
approval (Please Note: An e-mail approval

from Presenting Author is acceptable)
• IMPORTANT: The ACR does not retain and
cannot provide poster presentation images.
• The following statement must be listed under each
Poster reprint:

Poster reprinted from the ACR/ARHP Annual Meeting
held November 6-11, 2015. The American College of
Rheumatology does not guarantee, warrant, or endorse

any commercial products or services. Reprinted by (insert
name of supporting company).

Use of the ACR Disclosure Key
It is suggested when referencing disclosures in the reprints,
that the ACR’s disclosure key be added to provide adequate
context for abstracts:
None: Nothing to disclose

1. Stock, stock options or bond holdings in a for-
profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as
officer, board member, trustee or public

spokesperson
7. Receipt of royalties
8. Speakers’ bureau
9. Other
(#1039-1044) Rheumatoid Arthritis – Clinical Aspects I –
Table of Contents
Treatment Advances and Strategies

(#1045-1050) Rheumatoid Arthritis-Small Molecules,

Biologics and Gene Therapy II: Small Molecular Targeted
ACR/ARHP ABSTRACT
Therapies
(#1051-1056) Sjögren’s Syndrome I: Basic Insights
SESSIONS
(#1057-1062) Spondylarthropathies and Psoriatic Arthritis

SUNDAY, NOVEMBER 8, 2015 – Clinical Aspects and Treatment: Clinical Aspects and
CoMorbidities
8:30 AM - 4:00 PM
(#1063-1068) Systemic Lupus Erythematosus – Clinical
ACR Poster Session A
Aspects and Treatment II: Patient-Reported Measures,
(#1-895)
Outcomes and Reporting

(#1069-1074) Systemic Lupus Erythematosus – Human
11:00 AM - 12:30 PM
Etiology and Pathogenesis: Genetics, Gene Expression, and
ACR Plenary Session I
Epigenetics
Discovery 2015
(#1075-1080) Systemic Sclerosis, Fibrosing Syndromes, and
(#896-901)
Raynaud’s – Clinical Aspects and Therapeutics I

(#1081-1086) Vasculitis I
2:30 - 4:00 PM

ACR Concurrent Abstract Sessions
4:30-6:00 PM
(#901-906) Cytokines, Mediators, Cell-cell Adhesion, Cell
ACR/ARHP Combined Abstract Session
Trafficking and Angiogenesis
(#1087-1092) ACR/ARHP Combined Abstract Session:
(#907-912) Epidemiology and Public Health I: Rheumatoid
Rehabilitation
Arthritis Comorbidities and Mortality

(#913-918) Fibromyalgia: Insights into Diagnostic Criteria
and Symptom Epidemiology MONDAY, NOVEMBER 9, 2015
(#919-924) Health Services Research I: Digital Health and 8:30 AM - 4:00 PM
Patient, Provider Factors in Rheumatic Disease ACR/ARHP Poster Session B
(#925-930) Imaging of Rheumatic Diseases I: Ultrasound (#1093-1993)
(#931-936) Innate Immunity and Rheumatic Disease
(#937-942) Miscellaneous Rheumatic and Inflammatory 11:00 AM - 12:30 PM
(#943-948) Muscle Biology, Myositis and Myopathies I ACR Plenary Session II
(#949-954) Osteoarthritis – Clinical Aspects: Treatments and Discovery 2015
Epidemiology (#1994-1999)
(#955-960) Pediatric Rheumatology – Clinical and
Therapeutic Aspects I: Juvenile Idiopathic Arthritis 2:30 - 4:00 PM
(#961-966) Rheumatoid Arthritis – Human Etiology and ACR Concurrent Abstract Sessions
Pathogenesis I (#2000-2005) Antiphospholipid Syndrome: Recent Findings
(#967-972) Rheumatoid Arthritis-Small Molecules, Biologics (#2006-2011) Biology and Pathology of Bone and Joint:
and Gene Therapy I: Biologics Osteoarthritis Pathogenesis
(#973-978) Spondylarthropathies and Psoriatic Arthritis – (#2012-2017) Cytokines, Mediators, Cell-cell Adhesion, Cell
Clinical Aspects and Treatment: Treatment of Ankylosing Trafficking and Angiogenesis II
Spondylitis (#2018-2023) Epidemiology and Public Health II: RA and
(#979-984) Spondylarthropathies Psoriatic Arthritis – Lifestyle Factors
Pathogenesis, Etiology (#2024-2029) Imaging of Rheumatic Diseases II: MRI,
(#985-990) Systemic Lupus Erythematosus – Clinical PET and CT
Aspects and Treatment I: Epidemiology and Prognosis (#2030-2035) Infection-related Rheumatic Disease
(#991-996) T cell Biology and Targets in Autoimmune (#2036-2041) Miscellaneous Rheumatic and Inflammatory
Disease I Diseases Oral Session II
(#2042-2047) Pediatric Rheumatology – Clinical and
ARHP Concurrent Abstract Session Therapeutic Aspects II: Pediatric Systemic Lupus
(#997-1002) ARHP: Exemplary Abstracts Erythematosus
(#2048-2053) Rheumatoid Arthritis (RA) – Clinical Aspects
4:30 - 6:00 PM II: Infection, Malignancy and Other Comorbidites in RA
ACR Concurrent Abstract Sessions (#2054-2059) Rheumatoid Arthritis – Small Molecules,
(#1003-1008) Osteoarthritis – Clinical Aspects I: Imaging and Biologics and Gene Therapy III: Biosimilars
Epidemiology (#2060-2065) Spondylarthropathies and Psoriatic Arthritis –
(#1009-1014) Education Clinical Aspects and Treatment: Clinical Aspects
(#1015-1020) Pain: Basic Aspects (#2066-2071) Systemic Lupus Erythematosus – Clinical
(#1021-1026) Pediatric Rheumatology – Pathogenesis and Aspects and Treatment III: Biomarkers
Genetic (#2072-2077) Systemic Lupus Erythematosus – Human
(#1027-1032) Quality Measures and Quality of Care Etiology and Pathogenesis: Modulators of Disease
(#1033-1038) Rheumatoid Arthritis – Animal Models I
ARHP Concurrent Abstract Session (#3116-3121) Spondylarthropathies and Psoriatic Arthritis
(#2078-2083) ARHP II: Lupus – Clinical Aspects and Treatment: Psoriatic Arthritis –
Comorbidities
4:30 - 6:00 PM (#3122-3127) Systemic Lupus Erythematosus – Clinical
ACR Concurrent Abstract Sessions Aspects and Treatment V: Neuropsychiatric Lupus
(#2084-2089) Biology and Pathology of Bone and Joint: Bone (#3128-3133) Systemic Sclerosis, Fibrosing Syndromes and
Remodeling Raynaud’s – Pathogenesis, Animal Models and Genetics II
(#2090-2095) Epidemiology and Public Health III: Risk (#3134-3139) Systemic Sclerosis, Fibrosing Syndromes, and
Factors, Treatment and Outcomes of Gout and Osteoarthritis Raynaud’s – Clinical Aspects and Therapeutics II
(#2096-2101) Genetics, Genomics, and Proteomics (#3140-3145) Vasculitis III
(#2102-2107) Health Services Research II: Rheumatoid
Arthritis Treatment and Healthcare Utilization ACR/ARHP Combined Abstract Session
(#2108-2113) Metabolic and Crystal Arthropathies I: (#3146-3151) ACR/ARHP Combined Abstract Session:
Therapeutics Pediatric Rheumatology
(#2114-2119) Orthopedics, Low Back Pain and Rehabilitation
(#2120-2125) Reproductive Issues in Rheumatic Disorders: 4:30 - 6:00 PM
Basic and Clinical Aspects ACR Concurrent Abstract Session
(#2126-2131) Rheumatoid Arthritis – Clinical Aspects III: (#3152-3157) B Cell Biology and Targets in Autoimmune
Cardiovascular Disease and RA Disease: Novel B Cell roles in Rheumatoid Arthritis and
(#2132-2137) Rheumatoid Arthritis – Human Etiology and Systemic Lupus Erythematosus
Pathogenesis II (#3158-3163) Epidemiology and Public Health IV: Risk
(#2138-2143) Rheumatoid Arthritis – Small Molecules, Factors and Comorbidities for Systemic Lupus Erythematosus
Biologics and Gene Therapy IV: Safety of Targeted Therapies and Psoriatic Arthritis
(#2144-2149) Spondylarthropathies (SpA) and Psoriatic (#3164-3169) Metabolic and Crystal Arthropathies II:
Arthritis (PsA) – Clinical Aspects and Treatment: Treatment Mechanisms and Associations
of PsA and SpA (#3170-3175) Osteoporosis and Metabolic Bone Disease –
(#2150-2155) Systemic Sclerosis, Fibrosing Syndromes and Clinical Aspects and Pathogenesis I
Raynaud’s – Pathogenesis, Animal Models and Genetics I (#3176-3181) Pediatric Rheumatology – Clinical and
(#2156-2161) Vasculitis II Therapeutic Aspects IV: Imaging and Novel Clinical
Interventions
ACR/ARHP Combined Abstract Session (#3182-3187) Rheumatoid Arthritis – Clinical Aspects V:
(#2162-2167) ACR/ARHP Combined Abstract Session: Goal = Remission
Epidemiology and Pubic Health (#3188-3193) Rheumatoid Arthritis Animal Models II
(#3194-3199) Rheumatoid Arthritis-Small Molecules,
ARHP Concurrent Abstract Session Biologics and Gene Therapy VI: Strategies
(#2168-2173) ARHP III: Epidemiology and Public Health (#3200-3205) Sjögren’s Syndrome II: Clinical Discoveries
(#3206-3211) Spondylarthropathies and Psoriatic
TUESDAY, NOVEMBER 10, 2015 Arthritis – Clinical Aspects and Treatment: Clinical
Aspects, Imaging and Biomarkers
8:30 AM - 4:00 PM
(#3212-3217) Systemic Lupus Erythematosus–Animal Models
ACR/ARHP Poster Session C
(#3218-3223) Systemic Lupus Erythematosus–Clinical
(#2174-3073)
Aspects and Treatment VI: Novel Therapies

(#3224-3229) Vasculitis IV
11:00 AM - 12:30 PM

ACR Plenary Session III
ARHP Concurrent Abstract Session
Discovery 2015
(#3230-3235) ARHP IV: Clinical Practice and Patient Care
(#3074-3079)

WEDNESDAY, NOVEMBER 11, 2015
2:30 - 4:00 PM
9:00-10:30 AM
ACR Concurrent Abstract Sessions
ACR Concurrent Abstract Sessions
(#3080-3085) 2015 Rheumatology Research Foundation
(#3236-3246) Rheumatoid Arthritis (RA) – Clinical Aspects
Edmond L. Dubois, MD Memorial Lectureship: Systemic
VI: Death Be Not Proud – Mortality and Treatment Outcomes
Lupus Erythematosus – Basic Science
in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis
(#3086-3091) Fibromyalgia: Clinical Issues
Research Introductory Talk)
(#3092-3097) Pediatric Rheumatology – Clinical and

Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic
ARHP Concurrent Abstract Session
Diseases
(#3241-3246) ARHP V: Physical Activity
(#3098-3013) Rheumatoid Arthritis – Clinical Aspects IV:

Biomarkers, Disease Progression and Treatment Response
11:00 AM - 12:30 PM
(#3104-3109) Rheumatoid Arthritis – Human Etiology and
ACR Concurrent Abstract Sessions
Pathogenesis III
(#3247-3252) Pain: Clinical Aspects
(#3110-3115) Rheumatoid Arthritis-Small Molecules,
Biologics and Gene Therapy V: Immunogenecity
(#3253-3258) Rheumatoid Arthritis – Clinical Aspects VII:
Disease Activity and Updates in Measurement
(#3259-3264) Systemic Sclerosis, Fibrosing Syndromes, and
Raynaud’s – Clinical Aspects and Therapeutics III

ARHP Concurrent Abstract Session
(#3265-3270) ARHP VI: Physical Function and Disability

ACR LATE-BREAKING
ABSTRACT SESSIONS

TUESDAY, NOVEMBER 10, 2015
8:30 AM - 4:00 PM
ACR/ARHP Poster Session C
(#7L-15L) ACR Late-breaking Abstract Poster Presentations*

4:30 - 6:00 PM
ACR Concurrent Abstract Session
(#1L-6L) ACR Late-breaking Abstract Oral Presentations*

*Please Note: ACR Late-breaking abstracts are listed below
in numberic order instead of presentation order.
Abstract Number: 1
The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of
B Cells at the Inflammatory Foci
Estefanía Armas-González1, Ana Díaz-Martín2, María Jesús Domínguez-Luis3, María Teresa Arce-Franco2 and
Federico Díaz-González4, 1Universidad de La Laguna, Pharmacology Department, Tenerife, Spain, 2Hospital
Universitario de Canarias, Rheumatology Service, Tenerife, Spain, 3CIBICAN, Center of Biomedical Research of the
Canary Islands, University of La Laguna, Tenerife, Spain, 4Investigation Unit, Sociedad Española de Reumatológía,
Madrid, Spain
First publication: September 29, 2015
SESSION INFORMATION
Session Date: Sunday, November 8, 2015
Session Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose:
Experimental data suggest that B cells must migrate and accumulate into the synovial membrane to exert their
pathogenic role in rheumatoid arthritis (RA). Leukocyte extravasation requires a number of coordinated adhesives
events between circulating leukocytes and endothelial cells, a process known as the adhesion cascade. While the
molecules involved in the sequential steps of the adhesion cascade for neutrophils and T lymphocytes have been well
established, little is known about this process in B cells.
Objective: To determine the adhesion molecules involved in the interactions between B cells and endothelium under
dynamic condition resembling those of postcapillary venules during the inflammatory response.
Methods:
The surface expression levels of very late antigen (VLA)-4, intercellular adhesion molecule (ICAM)-1 and L-selectin
were assessed by double-colour staining flow cytometry analysis in CD20 + cells from the peripheral blood (PB) and
synovial fluid (SF), simultaneously obtained from 10 RA and 8 psoriatic arthritis (PsA) patients. Dynamic interactions
between B cells negatively immunoselected from buffy coats, and 12h TNF-a-activated human umbilical vein
endothelial cell (HUVEC) monolayers were studied in a two-parallel plate flow chamber. To study molecules involved
in the B-cells-HUVEC dynamic interaction, B cells were preincubated with monoclonal antibodies (mAbs) anti-CD20
or blocking mAbs anti- L-selectin, VLA-4 and ICAM-1; and HUVEC, with anti-vascular adhesion molecule (VCAM)-
1.
Results:
Flow cytometry analysis showed that the VLA-4 surface expression level in B-cells from SF in both RA (105±30%)
and PsA (135±45%) patients was not significantly different with respect to PB (considered 100%). Interestingly, the
surface expression level of ICAM-1 was significantly higher in SF relative to PB, in both RA (280±85%;) and PsA
(300±65%) patients, while L-selectin surface expression diminished in SF compared to PB in RA (40±5%) and PsA
(45±5%). In flow chamber experiments, no differences were observed in the process of rolling when B cells were
incubated with anti-CD20 antibodies, or with blocking mAbs anti-L-selectin and anti-ICAM-1 with respect to cells
incubated with mAb matching controls. However, the presence of blocking anti-VLA-4 mAb or anti-VCAM-1 mAbs
abrogated the interaction of B cells with activated endothelial cells.
Conclusion:
These results suggest that 1) B-cells with increased ICAM-1 expression and decreased L-selectin expression are
preferentially recruited in the inflamed synovial microenvironment; and 2) the integrin VLA-4, vis-à-vis its endothelial
counter receptor VCAM-1, plays a key role in the initial process of B-cell extravasation to inflammatory foci.
Disclosure: E. Armas-González, None; A. Díaz-Martín, None; M. J. Domínguez-Luis, None; M. T. Arce-Franco,
None; F. Díaz-González, None.
View Abstract and Citation Information Online - http://acrabstracts.org/abstract/the-integrin-very-late-antigen-4-
plays-a-key-role-in-the-recruitment-of-b-cells-at-the-inflammatory-foci
Abstract Number: 2
The Neutrophil Protein S100A12 Has Stronger Associations with a
Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial
Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients
Hilde Haugedal Nordal1,2 and Hilde Berner Hammer3, 1Broegelmann Research Laboratory, Department of Clinical
Science, University of Bergen, Bergen, Norway, 2Department of Rheumatology, Haukeland University Hospital,
Bergen, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
First publication: September 29, 2015
SESSION INFORMATION
Session Date: Sunday, November 8, 2015
Session Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose:
S100A12, a neutrophil protein, has proinflammatory effects on immune cells and can activate endothelial cells. The
mechanism of action suggests vascular endothelial growth factor (VEGF) as a marker of synovial neovascularization in
rheumatoid arthritis (RA). S100A12 and VEGF have both been associated with disease activity in RA. We wanted to
compare S100A12 and VEGF as biomarkers in a large longitudinal study of RA patients, and explore their association
with inflammatory activity expressed as synovial power Doppler (PD) scores.
Methods:
A total of 141 patients with RA (all met the ACR 1987 criteria, 81% women, mean (SD) age 52 (12) years, 79% anti-
CCP positive) were examined clinically and with ultrasound (US) before starting biologic treatment (67% anti-tumor
necrosis factor therapy) and after 1, 2, 3, 6 and 12 months. Inflammation of wrist (radiocarpal, intercarpal, radioulnar),
metacarpophalangeals 1-5, proximal interphalangeals 2-3, elbow, knee, ankle, metatarsophalangeals 1-5, extensor carpi
ulnaris and tibialis posterior tendons bilaterally, expressed as gray scale (GS) and PD scores, was scored
semiquantitatively 0-3. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were analyzed by in-house
methodology. Sera from all examinations were frozen at -80 ˚C and S100A12 was analyzed by an enzyme-linked
immunosorbent assay and VEGF by multiplex analysis. A total of 141 blood donors were controls (81% women, mean
(SD) age 52 (12) years). Mann-Whitney test was used to evaluate differences between patients and controls, Wilcoxon
signed rank test to study changes from baseline and Spearman’s rank test for correlation analysis.
Results:
At baseline, median (interquartile range) values of S100A12 were 275 (142-463) ng/mL in patients and 129 (75-222)
ng/mL in controls (p<0.0001), while VEGF values were 81 (43-162) pg/mL in patients and 68 (46-108) pg/mL in
controls (p=0.08). S100A12, VEGF, CRP, ESR, DAS28, sum GS and PD scores were reduced from baseline at all
time points (all p<0.0001). S100A12 correlated with ESR and CRP at all times (r=0.23-0.56, p≤0.003) except with
CRP after 12 months. VEGF did not correlate with ESR/CRP at any examination, except with CRP at 2 months (r=0.17,
p=0.05). S100A12 correlated with DAS28 at all times (r=0.27-0.35, p≤0.001), with sum GS scores (r=0.26-0.39,
p≤0.002) except after 12 months, and with sum PD scores at all times (r=0.17-0.42, p ≤0.04). No correlations were
found between VEGF and DAS28. VEGF correlated with sum GS scores (r=0.18-0.21, p≤0.03) before 12 months and
with sum PD scores (r=0.17-0.19, p≤0.05) only before 3 months.
Conclusion:
S100A12 was a stronger biomarker than VEGF in RA patients treated with biologic medication during one year, having
significant associations with clinical and US examinations. VEGF was expected to be associated with PD activity, but
only weak correlations were presently found.
Disclosure: H. H. Nordal, None; H. B. Hammer, AbbVie, 2.